Chapter 10 - THE PRICE OF A GRANDDAUGHTER
The caller’s number traced to a prepaid device activated near Carter Biomedical’s headquarters. That did not prove Arthur ordered the call, but security records placed Malcolm Redd in the area at the relevant time. Redd’s attorney declined comment when Brooks requested another interview.
Arthur publicly condemned threats against his family.
Privately, he asked Evelyn to meet.
She agreed only with counsel present.
The meeting took place in his home library, the room where she once did homework while he worked late. Childhood photographs covered the shelves. Lily’s photograph remained absent.
Arthur began with the medical treatment. He said Lily was deteriorating and the clinical team believed the investigational medication offered a chance when conventional treatment was failing.
The claim contained some truth.
Lily had been ill.
Doctors had considered additional intervention.
Yet the records did not show an immediate emergency so severe that parental consent could reasonably be bypassed.
Arthur knew that.
He finally admitted the approval process was incomplete.
“I made the decision I thought would save her.”
“You decided for both parents.”
“Yes.”
“Then forged our approval.”
“I had lawyers correct the file afterward.”
Evelyn stared at him.
He still called fraud a correction.
Arthur moved to the acquisition. Carter Biomedical funded research, hospitals, and employee benefits worldwide. A scandal could damage thousands of people uninvolved in Lily’s care. He argued the family should resolve the matter privately because public exposure would not restore the years already lost.
Evelyn asked about the surveillance.
Arthur said he needed to know Lily was safe.
“Why didn’t you tell me where she was?”
“Because you would have gone to her.”
“Yes.”
“And Daniel would have run again.”
“You don’t know that.”
“I know him.”
Evelyn looked at her father for a long time.
“No. You know what you needed him to be.”
The real motive had finally taken shape. Arthur was not protecting Lily from Daniel or Evelyn. He was protecting the company, the acquisition, and his own identity as the man who made difficult decisions for everybody else.
His granddaughter became an obstacle whenever her needs conflicted with that identity.
Arthur then offered Evelyn a private trust for Lily worth $12 million.
The money would fund education, medical care, and future security. It would be administered independently, he promised, and would not require direct contact with him.
The condition appeared on page fourteen.
Confidential resolution of all claims related to Carter Biomedical’s pediatric treatment.
Evelyn pushed the document away.
“You are putting a price on her silence.”
Arthur’s expression hardened.
“I am trying to give her something after Daniel took six years from you.”
“You took years too.”
He said nothing.
Then Evelyn asked the question that ended their meeting.
“If the company had never been at risk, would you have told me where she was?”
Arthur looked toward the window.
He could not answer.
The chapter’s final complication arrived from the independent auditors. Carter Biomedical had disclosed Lily’s case in its acquisition materials, but the file listed the adverse reaction as unrelated to the investigational drug.
The safety classification itself had been altered.
May you like
If deliberate, the problem extended beyond one false consent.
Arthur had concealed medical risk from the very people evaluating whether his company was safe to acquire.
